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Abstract: Secondary sclerosing cholangitis (SSC) is a term used for a group of chronic chole-
static disease affecting the intra- and/or extrahepatic biliary tree with inflammation and progres-
sive stricture formation, which can lead to biliary cirrhosis. A newly recognized form of SSC 
is secondary sclerosing cholangitis in critically ill patients (SSC-CIP). Pathogenesis is believed 
to involve ischemic injury of intrahepatic bile ducts associated with prolonged hypotension, 
vasopressors administration, and/or mechanical ventilation in patients treated in the intensive 
care unit (ICU). Patients diagnosed with SSC-CIP have no prior history of liver disease and no 
known pathologic process or injury responsible for bile duct obstruction prior to ICU treatment. 
Reasons leading to ICU treatment are many including multitrauma, burn injury, cardiac surgery, 
severe pneumonia, other infections, or bleeding after abdominal surgery. Patients have in com-
mon prolonged ICU admission. SSC-CIP is associated with rapid progression to liver cirrhosis 
and poor survival with limited treatment options except a liver transplantation. Transplant-free 
survival is around 17–40 months, which is lower than in other SSC patients. During the initial 
stages of the disease, the clinical symptoms and biochemical profile are not specific and easily 
missed. Biliary casts formation may be considered pathognomonic for SSC-CIP since most 
patients have them in early stages of the disease. Increased awareness and early detection of 
the disease and its complications is considered to be crucial to improve the poor prognosis.
Keywords: secondary sclerosing cholangitis, SSC-CIP, chronic cholestatic disease, sclerosing 
cholangitis
Introduction
Sclerosing cholangitis is a group of chronic cholestatic disorders affecting the intra- 
and/or extrahepatic biliary tree, which can lead to biliary cirrhosis and liver failure.1–11 
Sclerosing cholangitis can be divided into the more well-known primary sclerosing 
cholangitis (PSC), which is an idiopathic form mostly associated with inflammatory 
bowel disease,12,13 and secondary sclerosing cholangitis (SSC), the acquired form where 
the etiology can usually be identified.14 Infections, toxicity, and ischemia of the bile ducts 
are the most common causes of SSC.1–11 A recently recognized form of SSC has been 
observed in patients after long treatment in intensive care units (ICUs) called second-
ary sclerosing cholangitis in critically ill patients (SSC-CIP). As critical care medicine 
keeps improving, it results in more patients treated and surviving intensive care. This 
results in increasing reports of ICU-associated diseases, including SSC-CIP.14,15
In severe form of SSC-CIP, treatment options are limited to liver transplantations 
(LT), although this is a rare indication for LT. SSC-CIP is a relatively newly described 
condition with one of the first cases reported in the year 1997 by Schmitt et al16 and 
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others have confirmed theses observations.17,18 SSC-CIP is 
most likely under diagnosed and under reported.17,18 This 
review is meant to be a state-of-the-art on the pathogenesis, 
diagnosis, treatment, and outcomes of patients with SSC-CIP.
Patient characteristics
The prerequisite for the diagnosis of SSC-CIP is a lack of 
prior history of liver disease and no known pathologic process 
or injury responsible for bile duct obstruction.16–21 Patients 
have had in common a prolonged need for ICU treatment for 
a mean of 30–40 days14,15,18 and need for mechanical ventila-
tion. Mean age of these patients at diagnosis ranges from 46 
to 56 years old (range: 16–79 years) (Table 1).14,15,17,18,22,23 
Males seem to be more susceptible to this condition as male 
to female ratio is around 1.3:1 to 9:1.14,15,17,18,23 Patients were 
admitted for prolonged ICU treatment for a variety of condi-
tions, for example, polytrauma, burn injury, cardiac surgery, 
subarachnoid hemorrhage, severe pneumonia, acute respira-
tory distress syndrome (ARDS), infections, or bleeding after 
abdominal surgery.14,17,18,22–24
Pathogenesis
Two major concepts are thought to be the underlying patho-
physiological mechanism of SSC-CIP. The concept receiving 
the most attention is the so called “concept of ischemic chol-
angiopathy”. The hepatocytes of the liver receive dual blood 
supply, both from the portal vein and from the hepatic arter-
ies. On the other hand, the biliary epithelium receives blood 
supply solely from the peribiliary plexus, which is composed 
of branches from the hepatic arteries. As a consequence, the 
biliary epithelium is much more susceptible to ischemia than 
the hepatocytes.15,17 Our knowledge on the role of ischemia 
of the bile ducts is mostly based on liver transplant patients.25 
Early after LT, hepatic artery thrombosis, a well-known 
complication after LT can lead to interruption of the arterial 
blood supply resulting in bile duct necrosis.15,25 Ludwig et al7 
also showed that administration of the chemotherapy drug, 
floxuridine, in the hepatic artery resulted in bile duct necrosis 
and sclerosing cholangitis. Ischemia of the biliary epithelium 
can occur when the blood supply to the bile ducts is reduced 
resulting in bile cast formation due to necrosis and SSC as 
Ludwig et al reported.7,15,17 Chemical analysis has revealed 
proteins as the main composition of these biliary casts sup-
porting that it is due to necrosis of the biliary epithelium.17
The other concept is the so called concept of toxic bile. 
This concept focuses on the destruction of protective mecha-
nisms for cholangiocytes.15 Without protection, the detergent 
properties of hydrophobic bile acids might destroy the lipid 
membrane of cholangiocytes. The main protective mecha-
nism is secretion of phospholipids from the hepatocytes via 
the transporter lipid export pump MDR3, which form protec-
tive mixed micelles with bile acids. Also the biliary secretion 
of bicarbonate, via the transporter anion exchanger 2 (AE2), 
forms a protective alkaline bicarbonate film on the apical 
cholangiocyte membrane as a part of defense strategy.26 A 
disturbance in the fine balance between bile acids and protec-
tive mechanisms can lead to damage to the biliary epithelium, 
which in turn can lead to sclerosing cholangitis. This bal-
ance is believed to be threatened in critically ill patients by 
various conditions such as systemic inflammatory response 
syndrome (SIRS)/sepsis and severe hypotension.15,27 It has 
been proposed that individuals with genetic variants of the 
transporter lipid export pump MDR3 may have predisposi-
tion to formation of toxic bile under conditions of ischemia 
Table 1 Summary of published case series of SSC-CIP with number of patients, male to female ratio, age at diagnosis, liver 
transplantations performed, and mortality
Authors, year Patients, n Male:female 
ratio
Mean age at diagnosis 
(years)
LT, n (%) Mortality,  
n (%)
Scheppach et al, 200143 3 1:2 32 ± 7 1 (33) 0 (0)
Engler et al, 200323 9 5:4 56 ± 17 1 (11) 5 (56)
Benninger et al, 20056 5 4:1 48 ± 20 0 (0) 1 (20)
Jaeger et al, 200619 10 5:5 55 (M) 1 (10) 1 (10)
Gelbmann et al, 200717 26 20:6 47 ± 18 4 (15) 7 (27)
Esposito et al, 200814 10 9:1 50 ± 17 1 (10) 6 (60)
Kulasiz et al, 200842 29 21:8 52 (M) 3 (10) 19 (66)
Kirchner et al, 201122 11 10:1 46 ± 12 11 (100) 4 (36)
Voightlander et al, 201220 54 n/a 50 (M) 6 (11) 27 (50)
Weig et al, 201244 5 5:0 46 ± 10 0 (0) 5 (100)
Ben-Ari et al, 201524 4 4:0 38 ± 18 1 (25) 2 (50)
Leonhardt et al, 201518 16 11:5 46 ± 15 9 (56) 3 (19)
Note: Mean age is presented with standard deviation.
Abbreviations: SSC-CIP, sclerosing cholangitis in critically ill patients; LT, liver transplantation; M, median; n/a, not available.
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or inflammatory stress.28 This might explain why some ICU 
patients develop SSC-CIP and others with similar disease 
states recover without biliary deterioration.
Trigger mechanisms
A number of trigger factors have been proposed as causes 
for the development of SSC-CIP, including prolonged 
hypotension, vasopressors administration, and techniques 
in mechanical ventilation.15 Leonhardt et al15 noted that all 
their patients experienced an episode of severe hemodynamic 
instability with a decrease in mean arterial blood pressure 
(MAP) below 65 mmHg lasting for at least 60 minutes and 
often longer. They also noted that the onset of cholestasis was 
most closely time related in the time interval between severe 
hypotension and cholestasis.15 Ben-Ari et al24 also observed 
severe hypotension (less than 70 mmHg in systolic pressure) 
in all their patients.
Vasopressors administration is a common treatment in the 
ICU patients before the diagnosis of SSC-CIP.15,29 Epineph-
rine, norepinephrine, dopamine, and dobutamine all increase 
systemic blood pressure but do not have the same effect on 
hepatosplanchnic blood flow. Dopamine has been shown 
to have positive effect on liver perfusion.30 In contrast, epi-
nephrine and norepinephrine are believed to have a negative 
effect on splanchnic blood flow.31 Although catecholamines 
are believed to play a role in the pathogenesis of SSC-CIP, 
high-dose catecholamine (>0.2 μg/kg/min) do not seem to 
cause it, and although theoretically possible, there is a lack 
of experimental proof for this effect.15
Duration of mechanical ventilation in these patients has 
been reported from approximately 26 to 41 days.15,17,23 The 
PaO
2
/FiO
2 
ratio was <150 mmHg in all patients in one study 
and in 7/16 patient in another.15 All needed >10 cmH
2
O 
positive end-expiratory pressures (PEEP) in one study17 
and 50% of patients in another.15 A meta-analysis by Lin et 
al29 showed that all patients had high PEEP treatment with 
average treatment duration of 36 days and mean pressure of 
PEEP 12.8 cm H
2
O. Gelbmann et al17 also noted that many 
patients needed high-frequency oscillatory ventilation (9/17 
patients) and intermittent prone positioning (12/17 patients). 
It has been proposed that lung protective mechanical ventila-
tion with high PEEP, low tidal volume, and prone positioning 
can decrease splanchnic blood flow.32,33
Microbiological examination
In about 98% of SSC-CIP patients, bacteria and/or Candida 
species are detectable in the collected bile.21 Gelbmann et 
al17 performed a study on bile cultures collected through 
endoscopic retrograde cholangiopancreatography (ERCP) 
from patients with SSC-CIP. The test revealed growth of 
Enterococcus faeceum or Enterococcus faecalis in 71% of 
patients. A total of 67% of the isolates showed resistance 
to ciprofloxacin and gentamicin.17 In addition, half of the 
isolates showed resistance to imipenem and amoxicillin-
clavulanic acid. Other isolates were candida, methicillin-
resistant Staphylococcus aureus, Pseudomonas aeruginosa, 
and Stenotrophomonas maltophilia.17 Other studies have 
confirmed that Enterococcus and candida albicans are the 
main isolated microorganism in the bile.22 Cultures from 
drained abscesses in patients with SSC-CIP after burn injuries 
revealed hospital-acquired multiple-resistant bacteria such as 
P. aeruginosa and Acinobacter.24 It is unclear whether these 
pathogens play a role in the pathogenesis or just incidental 
findings of innocent bystanders or colonizers. At least they 
show a high rate of antibiotic resistance, which must be taken 
into count during the treatment of SSC-CIP patients.
Diagnosis
Clinical symptoms
In the initial stages of SSC, clinical symptoms are rare, and 
the only indication of cholestasis is elevated liver tests. This 
often leads to a delayed or a missed diagnosis. Patients with 
persistent cholestasis should be suspected having sclerosing 
cholangitis. The differential diagnoses among patients in the 
ICU with cholestatic liver tests are several such as cholestasis 
associated with sepsis,34 cholangitis due to choledocholi-
thiasis,35 and drug-induced liver injury (DILI).36 The most 
common type of agents leading to idiosyncratic liver injury 
are antibiotics,36,37 and these are commonly used in the ICU. 
Thus, DILI is an important differential diagnosis in these 
patients, particularly in those with normal hepatobiliary 
imaging. As disease progresses, clinical symptoms develop. 
The most common symptoms are jaundice, pruritus, and 
abdominal discomfort localized in the right upper quadrant 
of the abdomen.38,39 Recurrent biliary infections are typically 
observed in SSC patients.39 Patients with SSC-CIP present 
with persisting symptoms of cholestasis, despite recovery 
from their primary illness that needed ICU treatment. This is 
the main clinical finding that differentiates SSC-CIP patients 
from patients with endotoxin-associated jaundice, which 
resolves after clinical recovery.39
Liver tests and other laboratory 
parameters
No specific clinical and biochemical parameter indicates the 
presence of early sclerosing cholangitis. Major presenting 
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
8.
54
.2
1 
on
 2
3-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical and Experimental Gastroenterology 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
108
Gudnason and Björnsson
signs are persistent elevated gamma-glutamyl transferase 
(GGT) (peak 20–50 times upper limit of normal [ULN]) 
and alkaline phosphatase (ALP) (peak 5–21 times ULN)18 
along with elevated bilirubin levels (peak 3–39 times ULN) 
(Table 2).17 GGT is the first parameter to become elevated, 
usually around 7 days after initial life-threatening event, 
followed by ALP elevation within a few days. Bilirubin is 
the last of the three to become elevated showing a mean of 
16 days after initial life-threatening event.18 While these 
three parameters can become severely elevated, alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST) 
are usually only mildly or moderately elevated.18 Another 
finding made by Leonhardt et al18 was that cholesterol lev-
els was significantly elevated, with a mean of 536 mg/dL, 
compared to a normal value of 200 mg/dL within the first 
year of disease.
Imaging
ERCP has been considered to be the gold standard for diag-
nosing SSC-CIP. Compared with ERCP, the accuracy for 
diagnosing SSC-CIP was 30% for ultrasound and 36% for 
liver biopsies.20 In recent years, magnetic resonance cholan-
giopancreatography (MRCP) has been increasingly utilized 
as a diagnostic instrument and is preferred, prior to an ERCP, 
since it is noninvasive imaging and these are critically ill 
patient at risk when undergoing any invasive procedure.24 
Common initial findings during the early stage of the disease 
on ERCP are multiple ribbon-like intraductal filling defects 
known as biliary cast formation.18,40 These are followed by 
infections that can lead to multiple hepatic abscesses. In later 
stages, findings are multiple irregular strictures, dilations, 
beading, wall thickening, and destruction of the intrahepatic 
bile ducts with sparing of the common bile duct forming a 
“pruned tree” appearance.18,24,41 All patients have intrahepatic 
bile duct involvement, whereas only around a fifth of patients 
also have minor extrahepatic disease.18 Leonhardt et al18 
found out that a total of 88% of SSC-CIP patient developed 
imaging features of liver cirrhosis within 6 months of diag-
nosis. There is often a delay until an ERCP is performed, and 
final diagnosis of SSC-CIP has usually not been made until 
2–3 months after initial signs of cholestasis.18,22,24
Histopathology
Esposito et al14 examined 10 liver biopsies of patients diag-
nosed with SSC-CIP taken 1.5–57 months after diagnosis. 
Morphological changes in the portal area include inflamma-
tory-degenerative changes in the bile ducts, mild to moderate 
periductal inflammatory infiltrate, portal edema with mod-
erate portal enlargement, cholestatic features with ductular 
reaction, and cholate stasis and fibrosis without a specific 
periductal pattern.14 Acinar changes include hepatocellular 
and/or canalicular cholestasis, perivenular necroses, and 
bile infarcts.14 These results are comparable to the results of 
Gelbmann et al17 and Leonhardt et al.,18 Gelbmann et al noted 
that during the early phase, biopsy findings were suggestive of 
bile duct “obstruction”, including periportal bile duct infarcts 
and perivenular bilirubinostasis with bile pluggins of dilated 
canaliculi. Ductular proliferation, portal fibrosis, and throm-
botic occlusion of the portal hepatic arteries or veins were 
absent. Within 4–12 months after beginning of cholestasis, 
biopsies showed severe histological alterations including bile 
duct proliferation, portal inflammatory infiltrate, portal, and 
periductular fibrosis. Finally after 14–17 months, one of two 
biopsies showed incomplete liver cirrhosis. It was concluded 
that progression to liver fibrosis seems to be dependent on 
the extent of initial biliary injury.17,18 A persistent infection 
of the bile ducts also often aggravates the fibrotic process.17 
Studies have not shown any correlation between laboratory 
values and morphological evidence of cholestasis.14
Complications of SSC-CIP
The outcome of patients with SSC-CIP is often liver cirrhosis 
and hepatic failure with high mortality rate.20,42 However, 
other complications can arise during the disease process that 
must be taken into consideration as some of these are treat-
able. Acalculous cholecystitis has been noted in over half of 
patients with SSC-CIP within the first year and around half 
of those require emergency cholecystectomy.18 It seems that 
Table 2 Summary of published case series with peak liver parameters of patients with SSC-CIP
Authors, year ALP (U/L) GGT (U/L) Bilirubin (mg/dL) ALT AST
Engler et al, 200323 1660 445 10.2 n/a n/a
Gelbmann et al, 200717 1182 ± 1058 n/a 10.4 ± 9.1 n/a n/a
Kulasiz et al, 200842 758 ± 544 726 ± 815 12.3 ± 10.6 172 ± 191 171 ± 184
Ben-Ari et al, 201524 2484 ± 496 4045 ± 2057 19.7 ± 15.2 158 ± 29 207 ± 42
Note: All liver parameters are presented as mean with standard deviation if available.
Abbreviations: SSC-CIP, sclerosing cholangitis in critically ill patients; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; n/a, not available.
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the gallbladder epithelium is involved in the pathogenesis 
process of SSC-CIP. Therefore, SSC-CIP should be suspected 
in ICU patients with acalculous cholecystitis and unexplained 
cholestasis.18,23
Bacterial cholangitis is common in patients with SSC-
CIP, which is probably due to strictures and destruction of 
segmental and subsegmental bile ducts. As a result of ductal 
damage, peripheral bile duct branches lose their connection 
to the central ducts. The elimination of a biliary obstruction 
is needed for successful antibiotic treatment of cholangitis, 
and excluded ducts are hard to drain and therefore cannot 
receive penetration from antibiotics. This limits the effective-
ness of antibiotic treatment and increases the risk of so-called 
cholangiosepsis with high mortality rate. Furthermore, the 
stagnation of bile flow promotes cholangitic liver abscesses.18
Leonhardt et al18 noted that patients had severe weight 
loss of mean 18 kg within first year after initial injury, which 
was though not associated with the length of stay in the ICU.
Treatment
Treatment options for patients with SSC-CIP are unfortu-
nately rather limited. Patients with clinical evidence of bacte-
rial cholangitis are treated with broad spectrum antibiotics 
according to microbiologic testing if available.42 Various 
different endotherapies, including endoscopic dilations, 
endoscopic sphincterotomy of the sphincter of Oddi, intermit-
tent stenting, removal of biliary casts in the larger intrahepatic 
bile ducts with a dormia basket, and sludge extraction, have 
been performed in patients diagnosed with SSC-CIP.19,23,29,42 
Patients have biliary cast formations that are black-pigmented 
and necrotic material that obstruct the bile flow and increase 
risk of infection. The cast formations can in some cases be 
extracted during ERCP procedure.19,42 In patients with casts 
in the smaller bile ducts that cannot be reached during normal 
ERCP procedure a continuous saline rinsing through a naso-
biliary drainage for several days has been performed. How-
ever, saline rinsing has not shown much success in removing 
more of the intraductal material due to the insolubility and 
the adherence of the casts.17 These different procedures have 
shown to be associated with lower bilirubin and ALP levels 
and short-term clinical improvement, although controlled 
studies are lacking. However, these measures do not seem 
to prevent the progressive destruction of the biliary tree and 
progression of the disease.17,23 Ursodeoxycholic acid (UDCA) 
administration has also been given, although it has not been 
proven to reduce mortality.23,29,40,42 Up to 75% of patients have 
to be placed on the waiting list for liver transplant within the 
first year after the onset of cholestasis.18
Outcome and prognosis
SSC-CIP is a progressive cholestatic liver condition charac-
terized by necrosis of the bile duct epithelium, which leads to 
rapid destruction of intrahepatic bile ducts. When manifested, 
it usually runs a chronic, irreversible course, and the ultimate 
cure in the most severe cases is only LT. Transplant-free sur-
vival is around 17–40 months.18,42 One-year survival rate after 
LT for patients with SSC-CIP is approximately 85%, which is 
comparable with that of patients transplanted due to alcoholic 
liver cirrhosis.18,22 Without transplantation, 1-year survival is 
as poor as 55% and only 14% after 6 years.42 Compared to 
PSC and SSC in general, the survival is significantly shorter 
for SSC-CIP, with a median survival of 13 months for SSC-
CIP versus 72 months for SSC in general and 89 months 
for PSC patients.40 The most common cause of mortality is 
hepatic failure, and around half of patient who survive have 
cholestatic cirrhosis in a stable condition, and the rest are 
waiting for LT.29
Conclusion
SSC-CIP is a rather newly recognized condition that has been 
gaining more attention in recent years due to rise in ICU 
treatment-related diseases with improved ICU treatment. 
SSC-CIP is usually a progressive disease with an aggressive 
nature leading to liver cirrhosis and hepatic failure without 
LT.42 During the initial stages of the disease, the clinical 
symptoms and biochemical profile are not specific and do 
not differentiate much from endotoxin-associated jaundice, 
which is a common condition in critically ill patients. Thus, 
increased awareness and early detection of SSC-CIP and its 
complications are believed to be crucial to improve the poor 
prognosis. Biliary casts formation may be considered pathog-
nomonic for SSC-CIP since most patients have them in early 
stages of the disease and these casts have not been described 
in the literature in either PSC or IgG4 cholangiopathy.18
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